431 related articles for article (PubMed ID: 30375910)
21. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
[TBL] [Abstract][Full Text] [Related]
22. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
[TBL] [Abstract][Full Text] [Related]
23. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
[TBL] [Abstract][Full Text] [Related]
24. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M;
J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960
[TBL] [Abstract][Full Text] [Related]
28. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy.
Straus D; Collins G; Walewski J; Zinzani PL; Grigg A; Sureda A; Illes A; Kim TM; Alekseev S; Specht L; Buccheri V; Younes A; Connors J; Forero-Torres A; Fenton K; Gautam A; Purevjal I; Liu R; Gallamini A
Leuk Lymphoma; 2020 Dec; 61(12):2931-2938. PubMed ID: 32842815
[TBL] [Abstract][Full Text] [Related]
29. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
Connors JM; Ansell SM; Fanale M; Park SI; Younes A
Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
[No Abstract] [Full Text] [Related]
30. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Feldman T; Zou D; Rebeira M; Lee J; Fanale M; Manley T; Rao S; Feliciano J; Harris M; Kansal A
Am J Manag Care; 2020 Feb; 26(2):e41-e49. PubMed ID: 32059099
[TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.
Babashov V; Begen MA; Mangel J; Zaric GS
Curr Oncol; 2017 Feb; 24(1):e6-e14. PubMed ID: 28270727
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
[TBL] [Abstract][Full Text] [Related]
33. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of brentuximab vedotin for relapsed or refractory systemic anaplastic large-cell lymphoma in China.
Liu J; Zheng L; Chuang LH
J Med Econ; 2022; 25(1):99-107. PubMed ID: 34927526
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.
Delea TE; Amdahl J; Boyko D; Hagiwara M; Zimmerman ZF; Franklin JL; Cong Z; Hechmati G; Stein A
J Med Econ; 2017 Sep; 20(9):911-922. PubMed ID: 28631497
[TBL] [Abstract][Full Text] [Related]
36. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
37. [Our experience with the treatment of Hodgkin lymphoma patients].
Illés Á; Garai I; Miltényi Z
Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
[TBL] [Abstract][Full Text] [Related]
38. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Steiner RE; Hwang SR; Khurana A; Habermann TM; Epperla N; Annunzio K; Allen PB; Baird K; Paulino D; Alderuccio JP; Lossos IS; David K; Evens AM; Pandya K; Bair SM; Kamdar M; Ba Aqeel S; Torka P; Lynch R; Smith S; Feng L; Noorani M; Ahmed S; Nair R; Vega F; Wu S; Fang P; Pinnix CC; Gunther JR; Dabaja BS; Lee HJ
Blood Adv; 2023 Dec; 7(24):7485-7493. PubMed ID: 37603594
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD).
Sekiguchi Y; Iizuka H; Takizawa H; Sugimoto K; Sakajiri S; Inano T; Fukuda Y; Shirane S; Hamano Y; Tomita S; Izumi H; Okubo M; Nakamura N; Sawada T; Sekiguchi N; Noguchi M
Intern Med; 2020 Sep; 59(17):2165-2171. PubMed ID: 32461524
[TBL] [Abstract][Full Text] [Related]
40. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].
Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S
Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]